行情

BPMC

BPMC

蓝图医药
NASDAQ

实时行情|Nasdaq Last Sale

65.02
-0.39
-0.60%
交易中 13:06 01/28 EST
开盘
65.68
昨收
65.41
最高
66.41
最低
64.81
成交量
42.67万
成交额
--
52周最高
102.98
52周最低
63.05
市值
35.04亿
市盈率(TTM)
-8.3617
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BPMC 新闻

  • “病毒恐慌”现降温迹象 美元美股联袂上涨
  • FX168.28分钟前
  • 强生称正在研发新型冠状病毒防疫疫苗
  • 新浪财经.50分钟前
  • 里士满联储1月制造业指数升至2018年以来的最高水平
  • 新浪财经.1小时前
  • 美国1月消费者信心指数涨幅超预期 升至5个月来高点
  • 新浪财经.1小时前

更多

所属板块

生物技术和医学研究
+1.17%
制药与医学研究
+0.55%

热门股票

名称
价格
涨跌幅

BPMC 简况

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
展开

Webull提供Blueprint Medicines Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。